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Abstract 
The maternal physiology experiences numerous changes during pregnancy which are 
essential in controlling and maintaining maternal metabolic adaptations and fetal 
development. The human placenta is an organ that serves as the primary interface 
between the maternal and fetal circulation, thereby supplying the fetus with nutrients, 
blood and oxygen through the umbilical cord. During gestation, the placenta 
continuously releases several molecules into maternal circulation, including hormones, 
proteins, RNA and DNA. Interestingly, the presence of extracellular vesicles (EVs) of 
placental origin has been identified in maternal circulation across gestation. EVs can 
be categorised according to their size and/or origin into microvesicles (~150-1000 
nm) and exosomes (~40-120 nm). Microvesicles are released by budding from the 
plasmatic membrane, whereas exosome release is by fusion of multivesicular bodies 
with the plasmatic membrane. Exosomes released from placental cells have been 
found to be regulated by oxygen tension and glucose concentration. Furthermore, 
maternal exosomes have the ability to stimulate cytokine release from endothelial 
cells. In this review, we will discuss the role of EVs during fetal-maternal 
communication during gestation with a special emphasis on exosomes. 
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Introduction  
The human placenta is a unique, transient organ that ensues its development with the 16 
implantation of the blastocyst in the uterine wall [1]. Throughout pregnancy, it 17 
provides nutrition, gas exchange, waste removal, a source of haematopoietic stem 18 
cells and endocrine and immune support for the developing foetus, as well as the 19 
point of molecular exchange between the maternal and fetal systems [2].  20 
Functionally, the human placenta is a villous tree covered with an abundance of 21 
trophoblast cells that can be classified as cytotrophoblast (CT), extravillous 22 
trophoblasts (EVTs) and syncytiotrophoblasts. These cells have specific functions 23 
during gestation [3], where syncytiotrophoblasts are in direct contact with the 24 
maternal circulation for nutrients [4]. The human placenta can release a wide range of 25 
molecules which enable the maternal physiology to accommodate fetal requirements 26 
during gestation. Interestingly, it has been described that the placenta can also 27 
communicate with the maternal physiology via extracellular vesicles (EVs) [5-7].  28 
An increase in the release of EVs into maternal circulation as the pregnancy 29 
progresses has been noted in both healthy and pathological pregnancies, GDM, and 30 
PE [6-9]. Interestingly, the presence of exosomes has been identified in maternal 31 
plasma as early as 6 weeks of gestational age [9]. These vesicles encapsulate a diverse 32 
cargo of proteins, lipids and nucleic acids that are constitutively released into the 33 
maternal circulation. They are subsequently taken up by cells of the maternal immune 34 
and vascular systems, hence modulating the overall maternal physiological system to 35 
adapt to pregnancy-induced changes [6]. Nevertheless, in complicated pregnancies, 36 
this mode of cell signalling plays a role in the manifestation of physical symptoms of 37 
disease states. This is particularly because the release of the extracellular vesicles is 38 
dependent upon the microenvironment that they are exposed to [10]. 39 
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This review will discuss the current body of knowledge on EVs during gestation with 40 
emphasis on the trafficking of placental vesicles into maternal circulation to regulate 41 
immune and metabolic adaptations to pregnancy. However, there is a gap in the 42 
literature pertaining to the standardisation of isolation methods to enrich specific 43 
populations of EVs, such as exosomes. 44 
 45 
General characteristics of extracellular vesicles  46 
A growing amount of evidence has emerged identifying EVs as a form of intercellular 47 
communication [11]. EVs (50nm-2um) are lipid-bilayer structures released from cells 48 
into the extracellular environment. They contain an array of proteins, lipids, RNAs 49 
and DNA. They are released from several cell types, such as trophoblasts [12], 50 
erythrocytes [13] and endothelial cells [14]. Initially thought to be cellular ‘debris’, 51 
EVs were later observed to interact with and modulate the bioactivity of specifically 52 
targeted cells [15]. Recent research has elucidated that EVs also modulate key 53 
processes in pregnancy, including regulation of immune responses, 54 
migration/invasion of placental cells, and cellular adaptations to the physiological 55 
changes underlying gestation [16]. 56 
EVs comprise several different types of vesicles. Two major groups of interest are 57 
exosomes and microvesicles, which can be further distinguished by size, biogenesis 58 
and content [11]. Exosomes (40-120nm) are bioactive membrane nanovesicles formed 59 
from the endocytic pathway. The inward budding of the plasma membrane results in 60 
the formation of multivesicular bodies, which subsequently internalise to form 61 
intraluminal vesicles. These intraluminal vesicles are then released into the 62 
extracellular environment via exocytosis as exosomes. As a result of their unique 63 
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biogenesis, exosomes are enriched with proteins such as CD63, CD9, CD81. 64 
Furthermore, they contain a variety of internal markers such as Tumour Susceptibility 65 
Gene 101 (TSG101) and Apoptosis-linked gene 2-interacting protein X (ALIX). 66 
Exosomes can also be identified by distinct cup-shaped morphology and a buoyant 67 
density in a sucrose gradient ranging from 1.13-1.19 g/mL. On the other hand, 68 
microvesicles (MVs) (approximately 0.2-1um), which are the most heterogeneous 69 
population, are secreted from the plasma membrane through direct budding or 70 
shedding of the membrane in response to cellular activation or stress [17]. A wide 71 
range of EVs from placenta origin has been dentified in maternal circulation under 72 
both normal and pathological conditions. 73 
 74 
Placental vesicles in maternal circulation  75 
Exosomes and microvesicles are released under normal and pathological conditions, 76 
with more potent effects on the physiology of target cells than single-molecule 77 
mediators such as lipids, hormones or cytokines. Placental vesicles have been 78 
identified in maternal circulation across gestation [7]. Notably, the secretion of 79 
vesicles was found to be increased during pregnancies complicated by gestational 80 
diabetes [7] and preeclampsia [18]. Moreover, EV release during pregnancy is 81 
modulated by particular features of the cellular microenvironment such as low oxygen 82 
tension (i.e. hypoxia) or high glucose concentration [19].  83 
The concentration of EVs in circulation is higher in pregnant women compared to 84 
non-pregnant women [7, 20]. This increased concentration may be attributed to the 85 
population of placental exosomes, which have been identified in maternal circulation 86 
at early gestation (~6 weeks) [9]. EVs may play key roles in shaping the complex 87 
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physiological changes during pregnancy, including establishment of the fetal-maternal 88 
circulation. This process begins with EVT invasion and is complete within 10 weeks 89 
of gestation. The invasion of EVTs is crucial for the remodelling of the spiral arteries 90 
(SpA), as well as preventing contact with the maternal blood flow in the intervillous 91 
space. Establishment of the maternal blood flow towards the end of the first trimester 92 
occurs when cytotrophoblasts fuse to form when cytotrophoblasts fuse to form layers 93 
of multinucleated syncytiotrophoblasts. These layers are bathed in soluble proteins 94 
and nutrients and cover the majority of the surface of the placenta [21]. The maternal 95 
blood then has direct contact with EVTs and syncytiotrophoblasts, becoming the 96 
dominant site for the release of EVs into the maternal circulation.  97 
The release of EVs by EVTs in early pregnancy has been demonstrated through the 98 
detection of soluble proteins such as human leukocyte antigen (HLA-G) [22]. HLA-G 99 
is only expressed in EVTs, where HLA-G+-EVs have been detected in the maternal 100 
circulation throughout pregnancy decreasing with term [23]. The EVs released from 101 
EVT using the Swan71 cell line revealed that they can release exosomes [24]. The 102 
findings of this study, as well as the detection of HLA-G+ -EVs, strongly indicates 103 
that EVTs release both exosomes and microvesciles.  104 
The regulation and release of EVs are dependent on the microenvironment, where 105 
composition and concentration have been reported to be altered in the plasma of 106 
pregnant women compared to non-pregnant women [25]. Knight et al. [26] found that 107 
consistent with placental origin, increased levels of placenta-derived EVs have been 108 
detected in the uterine vein blood compared to the peripheral blood [26]. When 109 
comparing pregnant and non-pregnant women, the concentration of exosomes was 110 
found to be approximately 50-fold greater. This concentration increases with disease 111 
severity and oxidative stress [7]. Interestingly, it has been found that the concentration 112 
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of EVs in circulation of preeclampic women is approximately 40% greater than that 113 
of healthy, pregnant women. This suggests that EVs may be implicated in 114 
exacerbations of the maternal systemic innate immune system and vascular 115 
dysfunction [26].  116 
Moreover, levels of placental-alkaline phosphatase-positive (PLAP+)-EVs were 117 
detected in the maternal circulation throughout pregnancy [26]. These PLAP+-EVs 118 
have been isolated directly from the plasma of pregnant women at 26 and 28 weeks of 119 
gestation [20], where they continuously increase during the first 12 weeks of  120 
gestation [9]. The increased presence of these EVs may be due to the changes and 121 
adaptations in maternal physiology.  122 
Interestingly, a role of exosomes in the fusion of cytotrophoblasts has also been 123 
suggested [27]. The resulting changes are crucial for the remodelling of the spiral 124 
arteries to reduce resistance to increased flow of blood [28]. Other studies have also 125 
found increased circulating concentrations of placental-derived EVs during 126 
preeclampsia, causing abnormal placentation [26, 29] with altered protein content 127 
[30]. Additionally, studies have shown that different microenvironments can increase 128 
the secretion of EVs from CT cells, followed by changes in vesicle contents and 129 
bioactivity [18]. All of these findings suggest that EVs have a significant role during 130 
pregnancy. We have included here a summary of published studies characterising 131 
EVs during gestation (Table 1). However, despite recent progress in this field, the role 132 
of exosomes during pregnancy remains to be fully elucidated.  Indeed, there is a 133 
paucity of data defining changes in the release, role and diagnostic utility of exosomes 134 
present in the maternal circulation during complicated pregnancies.   135 
 136 
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Potential roles of EVs during gestation 
Placental EVs have been shown to constitute immunosuppressive factors released by 137 
the placenta to prevent fetal rejection. They also protect the semi-allogenic fetus 138 
through the suppression of various modulatory signals in the maternal immune system 139 
and inhibiting T-lymphocyte activation and natural killer cells that are detrimental to 140 
pregnancy [31]. As the foetus is antigenically distinct from the mother, it is necessary 141 
to deploy a tolerant immune response preventing the rejection of the developing 142 
organism [32]. Considering the significant increase in exosomes during pregnancy in 143 
parallel with gestational age [7, 9], several studies are presently seeking to elucidate 144 
the potential role of placental-derived exosomes in modulating the immune response. 145 
Emerging evidence indicates that the presence of specific ligands in PLAP+ exosomes, 146 
such as FasL, can trigger activation of peripheral blood mononuclear cells. The 147 
suppression of zeta-chain and JAK3 also increases apoptotic activity of Jurkat cells, 148 
leading to cytokine production and activation of certain proliferative T-cell 149 
subpopulations. Additionally, exosomes of placental origin generate an increase in 150 
expression of the suppressor of cytokine signaling 2 (SOCS2). However, it should be 151 
considered that these activities are reinforced by other ligands present as oligomeric 152 
aggregates in the membrane of these exosomes such as PD-L1 (B7-H1) [20] or 153 
TRAIL [33].  154 
Furthermore, immune adaptations during pregnancy are also modulated by 155 
differential expression and production of cytokines. This in turn may be mediated by 156 
maternal EVs. The Th1/Th2 paradigm in pregnancy is crucial in materno-fetal 157 
relationship. The early pregnancy stages take place in a pro-inflammatory 158 
environment. Later, this environment transitions to an anti-inflammatory environment 159 
which is conducive to fetal health and surivial. In the final stages of gestation 160 
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approaching parturition, the environment once agains pro-inflammatory [34]. 161 
Interestingly, placental-EVs are thought to play a role in the maternal systemic 162 
inflammatory response by modulating cytokine release [8, 19]. One way this may 163 
occur is through the expression of ULBP1-5 and MIC on the surface of placenta-164 
derived exosomes. This enables the exosomes to induce down-regulation of the 165 
receptor NKG2D present in natural killer (NK) cells, CD8+, and gamma delta (γδ)-T 166 
cells by way of selective and dose-dependent manner, without affecting the lytic 167 
pathway through perforin [35].  Hence, the  function of NK, CD8+ and γδ-T cells is 168 
attenuated. Additionally, the expression of components of the B7 family including 169 
B7-H3, a potent down-regulator of T-cell activation, has also been ratified. The 170 
incorportation of the HLA-G5 isoform within the cargo of exosomes has also been 171 
demostrated. This is notable since HLA-G class molecules have been shown to 172 
protect fetal tissue from destruction by maternal immune cells [36]. These studies 173 
have demonstrated that these cell surface proteins are differentially expressed 174 
according to the pregnancy stage [22]. Besides expressing transmembrane proteins 175 
that can interact with specific receptors on target cell subpopulations, exosomes have 176 
also been found to be transported inside signaling molecules such as cytokines.  177 
Moreover, placental EVs are immunosuppressive where they express a number of 178 
death messengers which impede maternal immunity and promote fetal survival [20]. 179 
For instance, the placental EVs carry Synctin-1. The recombinant Sycntin-1 has the 180 
ability reduce the production of TNF-α and IFN-γ contributing to a normal pregnancy 181 
outcome [37, 38]. Additionally, maternal EVs can also be pro-inflammatory, 182 
contributing to the development of systemic inflammation and pathological 183 
pregnancies. Pregnant women treated with placental EVs activate the phagocytic cells 184 
(granulocytes and monocytes) and induce the production of a wide range of pro-185 
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inflammatory cytokines including TNF-α, MIP-1α, IL-1α, -6, -8 and -1β, which are 186 
synthesised in higher amounts in pre-eclamptic pregnancies [39, 40]. Moreover, the 187 
activated macrophages and monocytes are key in modulating the induction of immune 188 
tolerance for the maintenance of normal pregnancy, as well as a protection against 189 
infection.Similarly, the internalisation of the EVs by monocytes prompts their 190 
migration and production of IL-1β, -6, G-CSF and TNF-α [41]. In addition to 191 
placental-EVs, macrophage-derived EVs interact with the placental cells and induce 192 
pro-inflammatory cytokines release [42].  193 
Pregnancy may be accompanied by features of metabolic disorders which occur due 194 
to alterations in the maternal inflammatory profile and heightened levels of pro-195 
inflammatory cytokines. Interestingly, this is more evident in obese pregnant women 196 
[43-45]. In obese pregnant women, the release of cytokines by adipose tissue and the 197 
placenta increases circulating pro-inflammatory cytokines level which in turn 198 
inappropriately activates inflammatory pathways [46]. Women with higher BMI were 199 
shown to have elevated levels of MCP-1 and TNF-α and activation of placental 200 
inflammatory pathways p38-MAPK and STAT3 [47]. These can potentially affect 201 
placental function and alter placental nutrient transports.  202 
Although these features of dysregulation have been previously noted in the literature, 203 
there is currently a paucity in the data to explain which molecules are responsible for 204 
functional effects. Given that the content of EVs is shaped by the cellular 205 
microenvironment and is target-cell specific, it is necessary to further elucidate the 206 
role of EV content in shaping the maternal metabolic profile. Thus, these data suggest 207 
that exosomes present in maternal circulation might alter the expression of the 208 
transcriptome and ultimately the cell phenotype by transferring specific proteins and 209 
miRNAs to target cells.  210 
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There are only few studies, however, that have assessed the potential role of 211 
exosomes present in fetal blood.. 212 
 213 
EVs in fetal circulation  214 
Maternal-fetal trafficking is the bidirectional passage of maternal cells to fetal 215 
circulation and fetal cells to maternal circulation. It is responsible for the migration of 216 
different cytokines and other factors to fetal circulation during pregnancy. This 217 
phenomenon suggests that pathophysiological changes occuring due to complicated 218 
pregnancies may be reflected in the fetal circulation. As discussed previously [48, 49], 219 
the presence of maternal microchimerism in fetal circulation play roles in providing 220 
immunologic tolerance against fetal semiallogenic grafts and the development of the 221 
immune system in the fetus during normal, healthy pregnancy. Similarly, cell-to-cell 222 
signalling from the mother to the fetuse in adverse pregnancy conditions provides an 223 
additional mechanism in protecting the foetus via compensatory mechanisms. 224 
Several studies have detected exosomes isolated from mesenchymal stem cells 225 
obtained from fetal blood, and have also discussed their role in different clinical 226 
implications including decrese liver fibrosis, inflammation and response to 227 
chemotherapy drugs [50-52]. Interestingly, the presence of placental exosomes has 228 
not been established in fetal circulation in human studies. However, Cleys et al. [53] 229 
observed the presence of placental extracellular vesicles in umbilical cord blood and 230 
serum in pregnant sheep [53]. Moreover, miRNA analysis in vesicles isolated from 231 
umbilical cord blood showed significant difference compared with results of miRNA 232 
analysis in maternal serum. Futher bioinformatics analysis established that vesicle-233 
associated miRNAs in fetal blood were associated with embryonic development. 234 
Interestingly, analysis of total exosomes isolated from human umbilical cord blood 235 
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showed that the exosomal protein expression profile is different in PE compared to 236 
normal healthy pregnancies [54]. The differentially expressed proteins were 237 
correlated with enzyme regulator activity, binding, extracellular regulation, biological 238 
regulation, cellular process and complement and coagulation cascades. 239 
The ability of exosomes to traffick different molecular cargoes based on the 240 
microenvironment, and further, their ability to modulate various physiological factors 241 
is already known. However, identifying placental specific exosomes in human fetal 242 
circulation including elucidating their roles in healthy and pathological pregnancies is 243 
a burgeoning area that needs to be addressed. 244 
 245 
 246 
Conclusions and perspectives  247 
 
EVs represent a mechanism of maternal-fetal interaction during gestation (Figure 1). 248 
As EVs have several origins and mechanisms of secretion within the microenviroment, 249 
we suggest that exosomes and their content might be a better representation of the 250 
function and metabolic state of the cell of origin. Several studies have clearly 251 
established the presence of EVs released from the placenta into maternal circulation. 252 
Further, it has been illustrated that these EVs have a wide range of functions including 253 
inmmunological regulation and maternal vascular adaptions to pregnancy. On the 254 
other hand, the characterisation of exosomes for a role in fetal development remains 255 
to be established. The field of EV-mediated cell-to-cell communication is of 256 
considerable contemporary interest and a growing field that may provide unique 257 
insights into the aetiology of disease, early detection and treatment monitoring. 258 
Understanding how EVs regulate key events during pregnancy may provide an 259 
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opportunity to understand the mechanisms involved in the maternal-fetal 260 
conmmunication under both normal and pathological conditions. 261 
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Table 1. Summary of studies of EVs in maternal and fetal circulation 
EVs Sample 
type 
Gestational 
age 
(weeks) 
 
Isolation 
method 
Pregnancy Biological 
process/results 
Reference 
Maternal Circulation 
Exosomes Plasma 28–30 
 
Immunomagnet
ic isolation 
Normal Maternal 
immune 
response 
[20] 
Exosomes Plasma 7-11 
36-38 
Centrifugation Normal miRNA 
analysis 
[55] 
STMB Plasma >37 Centrifugation PE High level of EVs in late 
onset PE 
[13] 
Exosomes Plasma 6-12 Centrifugation 
+ density 
gradient 
Normal Placental 
exosomes 
increase from 
6-12 weeks. 
[9] 
MPs Plasma >37 Centrifugation HIV 
infections 
Immunological 
role 
[56] 
MVs Plasma 12-18 Commercial kit Normal Immunological 
role 
[57] 
Exosomes Plasma >30 Centrifugation 
+ density 
gradient 
PE High levels of placental 
exosomes in 
PE 
[58] 
MVs Plasma  N/A Normal Angiogenesis [59] 
STMB Plasma >34 Centrifugation PE 
IUGR 
High levels of 
placental 
STMB 
[25] 
STMB Plasma >34 Centrifugation PE High levels of placental 
STMB 
[60] 
MPs Plasma 12-38 Centrifugation PE High levels of placental MPs 
[61] 
Exosomes Plasma 6-12 
22-28 
32-36 
Centrifugation 
+ density 
gradient 
Normal Exosomes increase across 
gestation 
[7] 
Exosomes Plasma 11-14 
22-28 
32-36 
Centrifugation 
+ density 
gradient 
GDM High levels of 
placental 
exosomes in 
GDM 
[8] 
Fetal  Circulation 
Exosomes-
derived 
MSC 
Umbilic
al vein 
blood 
At delivery Centrifugation 
+ filtration 
Normal Cell therapy [50] 
Exosomes-
derived 
MSC 
Umbilic
al vein 
blood 
At delivery Centrifugation 
+ filtration 
Normal Cell therapy [52] 
Exosomes-
derived 
MSC 
Umbilic
al vein 
blood 
At delivery Centrifugation PE Proteomic 
analysis 
[62] 
 
EVs = extracellular vesicles; STMB = Syncytiotrophoblast-derived vesicles; MPs = 490 
microparticles; PE = preeclampsia; GDM = gestational diabetes mellitus 491 
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Figure Legend 492 
 493 
 494 
 495 
Figure 1. Extracellular vesicle trafficking across fetal-maternal circulation. 496 
Extracellular vesicles (EVs) are released from the human placenta into maternal 497 
circulation (+). EVs present in maternal circulation can interact with the human 498 
placenta (+). The presence of placental EVs in fetal circulation has not been 499 
established yet (-). The concentration of total and placental EVs are higher in 500 
pregnancies with complications such as PE and GDM. EVs present in maternal 501 
circulation regulate biological processes such as maternal immune response, 502 
migration/invasion, metabolic adaptation and vascular reactivity during gestation. On 503 
the other hand, EVs present in fetal circulation are associated with fetal development. 504 
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